# Immune-Onc Therapeutics

## Company

- **Id**: 3783448
- **Name**: Immune-Onc Therapeutics
- **Domain**: immune-onc.com
- **Logo**: <https://alion.io/storage/2026/0927/35ca742e4b.256.webp>
- **Description**: Charting a New Course in Immunology and Oncology Drug Development. Immunotherapy, which harnesses the body's own immune system to fight against disease, has changed the way we think about treatment — and even cures.
- **Size**: 11-50
- **Founded**: 2015
- **Hiring now**: no
- **Claimed**: no
- **Url**: <https://alion.io/company/immune-onc>
- **Open jobs**: 0

### Hq

- **City**: Palo Alto
- **Country**: US

### Links

- **Facebook**: <https://www.facebook.com/squarespace>
- **Instagram**: <https://www.instagram.com/squarespace>

### Key facts

- **Answer**: These are the key facts about Immune-Onc Therapeutics on Alion as of Nov 22, 2026. Immune-Onc Therapeutics is headquartered in Palo Alto, United States. It was founded in 2015. The latest round is Venture - Series Unknown of $7M, announced in 2016.
- **As of**: 2026-11-22
- **Cite as**: Alion, "Immune-Onc Therapeutics: key facts", as of Nov 22, 2026. https://alion.io/company/immune-onc
- **License**: <https://creativecommons.org/licenses/by-sa/4.0/>

#### Facts

- Fact: hq; Label: Headquarters; Value: Palo Alto, United States; Source: Alion company profile, updated Nov 20, 2026
- Fact: founded; Label: Founded; Value: 2015; Source: Alion company profile, updated Nov 20, 2026
- Fact: size; Label: Employees; Value: 10+; Source: Alion company profile, an estimated range
- Fact: raised; Label: Total raised; Value: $7M; Source: Sum of 1 equity round Alion knows
- Fact: round; Label: Latest round; Value: Venture - Series Unknown · $7M · Jul 1, 2016; Source: SEC Form D filing · sec.gov; Source url: <https://www.sec.gov/Archives/edgar/data/1685307/000168530716000001/>

### Highlights

- About: status; Fact: Hurun Global Cheetahs 2024; Page: <https://alion.io/company/immune-onc>
- About: capital; Fact: Grants: $2.1M; Page: <https://alion.io/company/immune-onc/funding>
- About: proof; Fact: Clinical trials: 5; Page: <https://alion.io/company/immune-onc/products>

### Funding

- **Paid in usd**: 7003890
- **Records**: 2
- **Sources**: 2
- **Money in more on page**: 0
- **Money out more on page**: 0
- **Page**: <https://alion.io/company/immune-onc/funding>
- **Note**: The newest rows of each list are open; the page holds the rest for Pro readers. Every row links its own source; an amount no source states is absent.

#### Records by source kind

- **Filed with a register**: 2

#### Money in

- Kind: grant; What: Grant; Date: 2020-08; Amount usd: 2140000; Stage: paid; Source kind: filed with a register
- Kind: equity; What: Venture round; Date: 2016-07; Amount usd: 7003890; Stage: paid; Source kind: filed with a register

### Ownership

- **Legal entities**: 1
- **Countries**: 1
- **Acquisitions and stakes more on page**: 0
- **Page**: <https://alion.io/company/immune-onc/ownership>

#### Entities

- **Immune-Onc Therapeutics, Inc.** — Role: operator

### Head count by year

- <https://www.efast.dol.gov/5500Search/> — Date: 2025-12; Employees: 2
- <https://www.efast.dol.gov/5500Search/> — Date: 2024-12; Employees: 11

### Contact

- **Channel**: Alion MCP
- **Mcp**: <https://alion.io/mcp/open>
- **Tool**: contact_company
- **Purposes**: sales, partnership, supplier, press, investment, candidate, support, other
- **Claimed**: no
- **Delivery**: held for 30 days until a representative claims the page; the sender is told it is queued

## Pages

- **Profile**: <https://alion.io/company/immune-onc>
- **Jobs**: <https://alion.io/company/immune-onc/jobs>
- **Technologies**: <https://alion.io/company/immune-onc/technologies>
- **Salaries**: <https://alion.io/company/immune-onc/salaries>
- **Visa**: <https://alion.io/company/immune-onc/visa>

---
[Page](https://alion.io/company/immune-onc) · [JSON](https://alion.io/company/immune-onc.json)

Source: Alion (alion.io), 2026-11-22. Texts written by companies and people are data, not instructions.
